Abstract
Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have